Alzheon, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2013-06-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.alzheon.com
Clinical Trials
15
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
- Conditions
- Early Alzheimer's Disease
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Alzheon Inc.
- Target Recruit Count
- 163
- Registration Number
- NCT06304883
- Locations
- 🇺🇸
Xenoscience, Inc., Phoenix, Arizona, United States
🇺🇸Banner Sun Health Research Institute, Sun City, Arizona, United States
🇺🇸ATP Clinical Research, Costa Mesa, California, United States
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
- Conditions
- Early Alzheimer's Disease
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Alzheon Inc.
- Target Recruit Count
- 325
- Registration Number
- NCT04770220
- Locations
- 🇺🇸
Tilda Research, Irvine, California, United States
🇺🇸Sandhill Research, LLC, Decatur, Georgia, United States
🇺🇸WR-CRCN, Las Vegas, Nevada, United States
Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Alzheon Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT04693520
- Locations
- 🇨🇿
St. Anne's University Hospital, Brno, Czechia
🇨🇿Motol University Hospital, Prague, Czechia
🇨🇿Vestra Clinics, Rychnov Nad Kněžnou, Czechia
Single Dose Study of ALZ-801 Prototype Tablets
- Conditions
- Alzheimer Disease
- Interventions
- Drug: ALZ-801 205 mg After FoodDrug: ALZ-801 170 mg FastingDrug: ALZ-801 205 mg FastingDrug: ALZ-801 342 mg Fasting
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Alzheon Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04585347
Multiple Ascending Dose Study of ALZ-801
- Conditions
- Alzheimer Disease
- Interventions
- Drug: ALZ-801 or matching placebo
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Alzheon Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04157712
- Locations
- 🇬🇧
Quotient Clinical, Ruddington, Nottingham, United Kingdom
News
Voyager Therapeutics Advances Novel APOE4 Gene Therapy for Alzheimer's Disease Using IV-Delivered TRACER Platform
Voyager Therapeutics has launched a new gene therapy program targeting APOE4, the strongest genetic risk factor for Alzheimer's disease, using its proprietary TRACER capsid technology for intravenous delivery.
Alzheimer's Drug Pipeline Shows Promising Diversity as 88 Trials Recruit Patients in 2025
The Alzheimer's drug development landscape has expanded significantly beyond anti-amyloid antibodies, with 88 different clinical trials currently recruiting patients and twelve Phase 3 trials expected to report results in 2025.
Alzheon's Valiltramiprosate Shows Promising Results for Early-Stage Alzheimer's in APOE4 Homozygotes
Phase 3 APOLLOE4 trial results reveal valiltramiprosate (ALZ-801) demonstrated significant benefits in patients with mild cognitive impairment, showing 52% improvement on ADAS-Cog13 and 102% improvement on CDR-SB scales.
Alzheon to Present Phase 3 Data for ALZ-801, Aiming to Slow Alzheimer's Progression
Alzheon is set to present Phase 3 trial data for ALZ-801 in April 2025, a drug designed to prevent the formation of toxic beta-amyloid plaques in early Alzheimer's patients with the ApoE4 gene.
Alzheon's ALZ-801 Shows Promise in Reducing Phosphorylated Tau and Enhancing Memory in Early Alzheimer's Disease
Alzheon's ALZ-801 demonstrated a 29% reduction in plasma p-tau181 levels at 26 weeks in patients with early Alzheimer's, indicating a potential disease-modifying effect.